Loading
EG
Ebos Group Limited Stock: price and insider trades · Australia
1 insider bought €278 of shares over the last 90 days, the latest filed 24 Sept 2026.
Ebos Group Limited: what insiders have been doing
Every trade that managers of Ebos Group Limited disclose to ASX is tracked on this page. The company is based in New Zealand. Over the twelve months to 18 October 2026, the company's managers filed 2 filings, from 2 insiders.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €278) and 1 sale (1 insider). No amount is published for 1 filing, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €278, bought by Coline McConville and made public on 24 September 2026. The buyers include 1 senior executive.
Across the 2,222 companies tracked on its exchange, the median is 3 filings; at 2 filings, this issuer sits below that mark. Our records for Ebos Group Limited go back to 2026, with 1 purchase and 1 sale on the open market in total.
The latest purchase is recent: it was published 24 days ago, on 24 September 2026.
This summary is built from ASX disclosures alone and does not predict where the share price will go.
Insider Decl.
2
Thresholds
n/a
Buy Volume
€278
1 ops. · all time
Sell Volume
n/a
1 ops. · all time
Who traded when
BuySaleColine McConville1 buy
Matthew Muscio1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 10,307 of 24,148 companies
55.3
score / 100
Value77
Quality34
FCF yld9.7%
Earn yld7.9%
EV/EBITDA8.2x
ROE8.3%
Gross mgn13%
Net mgn1.7%
Debt/EBITDA3.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
A$16.59
Analyst consensus
5 analysts2.20/5
A$19.00Target A$23.19(+40%)A$26.00
Income statement
RevenueA$16.4B
Gross profitA$2.1B13% margin
EBITDAA$700.9M4% margin
Net incomeA$274M1.7% margin
Valuation
PER (trailing)14.4x
PER (forward)12.7x
P/Book1.2x
Beta0.17
Balance sheet & cash
Market capA$3.5B
Total debtA$2.3B
Free Cash FlowA$336.1M
Debt / Equity70%
Profitability & ownership
ROE8.3%
ROA3.1%
% insiders10.1%
% institutions19.7%
Last declaration on 24 September 2026
Declarations2 total
27 shares@ A$16.62100.0% of flowShareASXISIN NZEBOE0001S6ASX:2924-03139237-2A1698939
Canonical exit: 17 Dec 2026 (T+90)
1.17 sharesShareASXISIN NZEBOE0001S6ASX:2924-03135537-2A1697168
2 of 2 declarations
About Ebos Group Limited
Ebos Group Limited is an Australian company specializing in the distribution of pharmaceutical and healthcare products. It primarily operates in the Australian and New Zealand markets.
